166 related articles for article (PubMed ID: 32088220)
1. Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity.
Xu J; Chen Y; Yang R; Zhou T; Ke W; Si Y; Yang S; Zhang T; Liu X; Zhang L; Xiang K; Guo Y; Liu Y
Arch Biochem Biophys; 2020 May; 684():108314. PubMed ID: 32088220
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
3. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer.
Zhang H; Zhao B; Wei H; Zeng H; Sheng D; Zhang Y
J Ethnopharmacol; 2022 Apr; 287():114915. PubMed ID: 34954267
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin.
Liu T; Peng H; Zhang M; Deng Y; Wu Z
Eur J Pharmacol; 2010 Sep; 641(1):15-22. PubMed ID: 20483353
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
9. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M
Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589
[TBL] [Abstract][Full Text] [Related]
10. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis.
Sinha S; Khan S; Shukla S; Lakra AD; Kumar S; Das G; Maurya R; Meeran SM
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):41-56. PubMed ID: 27210504
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
Ueno M; Kariya R; Sittithumcharee G; Okada S
Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.
Yang T; Liu J; Yang M; Huang N; Zhong Y; Zeng T; Wei R; Wu Z; Xiao C; Cao X; Li M; Li L; Han B; Yu X; Li H; Zou Q
Oncotarget; 2017 Jan; 8(4):5800-5813. PubMed ID: 27418139
[TBL] [Abstract][Full Text] [Related]
15. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
16. (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol inhibits growth of colon tumors in mice.
Zheng J; Park MH; Son DJ; Choi MG; Choi JS; Nam KT; Kim HD; Rodriguez K; Gann B; Ham YW; Han SB; Hong JT
Oncotarget; 2015 Dec; 6(39):41929-43. PubMed ID: 26474284
[TBL] [Abstract][Full Text] [Related]
17. Stat3-siRNA inhibits the growth of gastric cancer in vitro and in vivo.
Sun Y; Guo BF; Xu LB; Zhong JT; Liu ZW; Liang H; Wen NY; Yun WJ; Zhang L; Zhao XJ
Cell Biochem Funct; 2015 Oct; 33(7):495-502. PubMed ID: 26486443
[TBL] [Abstract][Full Text] [Related]
18. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Xu GY; Tang XJ
Biomed Pharmacother; 2017 Aug; 92():95-107. PubMed ID: 28531805
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells.
Zhang M; Bian ZG; Zhang Y; Wang JH; Kan L; Wang X; Niu HY; He P
Mol Med Rep; 2014 Dec; 10(6):2905-11. PubMed ID: 25242136
[TBL] [Abstract][Full Text] [Related]
20. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
